Literature DB >> 26745646

Regression of ventriculomegaly following medical management of a patient with Hurler syndrome.

Jennifer Liang1, Ash Singhal1.   

Abstract

Hurler syndrome is the most severe form of mucopolysaccharidosis (MPS) Type 1. Progressive neurocognitive decline in this condition can be accompanied by macrocephaly, ventriculomegaly, and/or periventricular signal changes on MRI, which often leads to a neurosurgical referral. In this case, the authors describe a 2-year-old boy with ventriculomegaly and periventricular T2 signal changes, both of which decreased following medical management of Hurler syndrome. The authors discuss the possible mechanisms for this finding and the implications for neurosurgical treatment of this condition.

Entities:  

Keywords:  ERT = enzyme replacement therapy; GAG = glycosaminoglycan; HSCT = hematopoietic stem cell transplant; Hurler syndrome; MPS = mucopolysaccharidosis; congenital; mucopolysaccharidosis Type 1; pediatric neurosurgery; ventriculomegaly

Mesh:

Substances:

Year:  2016        PMID: 26745646     DOI: 10.3171/2015.9.PEDS15477

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  3 in total

1.  Cerebral magnetic resonance findings during enzyme replacement therapy in mucopolysaccharidosis.

Authors:  Yoshiko Matsubara; Osamu Miyazaki; Motomichi Kosuga; Torayuki Okuyama; Shunsuke Nosaka
Journal:  Pediatr Radiol       Date:  2017-07-21

2.  Successful management of MPS hydrocephalus by acetazolamide.

Authors:  Hakim Rahmoune; Nada Boutrid; Imene Gherbi; Samir Arezki; Mounira Amrane; Belkacem Bioud
Journal:  Childs Nerv Syst       Date:  2017-09-19       Impact factor: 1.475

3.  The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II).

Authors:  Miguel Sampayo-Cordero; Bernat Miguel-Huguet; Andrea Malfettone; José Manuel Pérez-García; Antonio Llombart-Cussac; Javier Cortés; Almudena Pardo; Jordi Pérez-López
Journal:  Int J Environ Res Public Health       Date:  2020-09-10       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.